Journal of Medicinal Chemistry · 2006 · 102 citations · 14 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyDrug DiscoveryStructure-activity RelationshipsApoptosis PharmacologyMitotic InhibitorsOncology PharmacologyAnticancer ActivityAntimitotic ActivityAntimitotic DrugsAntiproliferative AgentsAntiproliferative Drug ActionBcl-2 InhibitionBcl-2 Protein PhosphorylationTubulin Polymerization Inhibitors
Two series of carbazole sulfonamides related to Combretastatin A4 (1) were synthesized and evaluated for antiproliferative activity. Thirteen of the 26 new sulfonamides exhibited IC(50) values of <1 muM against CEM leukemia cells. Five compounds were evaluated against a panel of eight human tumor cell lines. 9-Ethyl-N-(3,4,5-trimethoxyphenyl)-carbazole-3-sulfonamide (11a) showed significant antitumor activity in two human xenograft models (MCF-7 and Bel-7402). Preliminary studies with 11a showed that the mode of action involves arrest of M-phase cell cycle and induction of apoptosis by increasing expression of p53 and promoting bcl-2 phosphorylation. Unexpectedly, 11a only weakly inhibits tubulin polymerization, which suggests that the mode of action of 11a differs from 1 and involves an unidentified target(s). Also, the SAR information gleaned from ring A-substituted analogues varies significantly from that of 1. Carbazole sulfonamides are a novel promising class of antimitotic agents with clinical development potential.
14
Mark Cushman, Dhanapalan Nagarathnam, Dhanushya Gopal et al. · Journal of Medicinal Chemistry · 1992 · 234 citations